TEVA PHARMACEUTICAL INDUSTRIES LTD
Its government footprint in one place: federal money, influence and market activity, each row linked to its source. Federal figures gathered Oct 25, 2026.
In plain words
In the last 12 months insiders sold 10 times ($20.5M) and bought 0 times ($0); 2 of the 7 sales whose filing shows the plan box were planned in advance.
Written by fixed rules from the figures on this page. No opinion, no prediction.
Government moneyⓘ
Obligations: money an agency has formally committed to pay under a contract. Not the same as money already paid, and not revenue.
ⓘ
Obligations: money an agency has formally committed to pay under a contract. Not the same as money already paid, and not revenue.SEC revenue and federal obligations
- FY2026Oct 2025 to Sep 2026$0$17.3B year to Dec 31, 2025
- FY2025Oct 2024 to Sep 2025$0$16.5B year to Dec 31, 2024
- FY2024Oct 2023 to Sep 2024$0$15.8B year to Dec 31, 2023
- FY2023Oct 2022 to Sep 2023$0Revenue for this year not on file
- FY2022Oct 2021 to Sep 2022$0Revenue for this year not on file
What these numbers are
Obligated means an agency committed the money to this company in that period (a signed contract action), as reported to USAspending. It is not a payment and not revenue: a contract can be funded for several years at once, and revenue is booked as the work is done. Some years can exceed revenue for that reason.
Prime contracts only, and only what is published. Work the company does as a subcontractor is not in these figures, and classified contracts are not published on USAspending at all. A low share can mean either. Contract values, ceilings and options are never added in.
Which units count: the USAspending recipient that is the company's SEC registrant; units of the company that USAspending's own records place under it (as parent, or in its family tree); and subsidiaries from the company's SEC Exhibit 21 that carry its name. Joint ventures, units now owned by someone else, and records that only share a name are held back. Both lists are below.
Earlier years count the units the company owns today. A unit we checked by hand (its USAspending parent is out of date) counts from the date the company bought it, or, where no filing gives that date, from the first date a filing shows the company owning it. Other units count for every year shown until their purchase dates are loaded.
Revenue bars are the company's own fiscal year from its 10-K, placed in the federal year it ends in; its fiscal year can end in a different month than the government's.
Fiscal year 2022 onward. Federal fiscal years run October to September; the company's own fiscal year may differ.
Units counted (1), held back (1)
- TEVA PHARMACEUTICAL INDUSTRIES LTD.DYLJM9RQJ167 · parent · the company's SEC name
Held back: a matching name we could not tie to this company firmly enough. A miss is better than a wrong link.
- NORTON HEALTHCARE, INC. (Exhibit 21 subsidiary, and USAspending lists no parent of ours)
Contracts ending in the next 18 months
None in the contracts we hold for this company.
Amount: obligated to date. From the contracts in HillSignal's records tied to this ticker; the full list of contracts ending across government is on Recompetes.
Influence
Foreign agents (FARA)ⓘ
FARA (Foreign Agents Registration Act): people who work in the US for a foreign government, party or company must register and report what they do and what they are paid.
ⓘ
FARA (Foreign Agents Registration Act): people who work in the US for a foreign government, party or company must register and report what they do and what they are paid.No FARA ties found in our records, through its lobbying firms or its own name.
Lobbying
No lobbying filings tied to this company in the Senate LDA records we hold.
PAC giving
No corporate PAC tied to this company in the FEC records we hold.
Marketⓘ
A 10b5-1 plan is a trading schedule an insider sets up in advance, so sales under it say less about the insider’s view.
ⓘ
A 10b5-1 plan is a trading schedule an insider sets up in advance, so sales under it say less about the insider’s view.Insider trades
- Savage Brian Interim Chief Legal OfficerSold $441K · Sep 18, 2026
- Mignone Roberto DirectorSold $14.4M · Sep 18, 2026
- Weiss Amir Chief Accounting OfficerSold $404K · Aug 21, 2026
- Satchi-Fainaro Ronit DirectorSold $15K · Aug 21, 2026
- Lippman Evan EVP, Business DevelopmentSold $680K · Aug 17, 2026
- Zaks Tal Zvi DirectorSold $593 · Aug 5, 2026
Open-market buys and sells from SEC Form 4 filings; grants and option exercises left out, and trades whose filed price failed our market check. A 10b5-1 plan is a trading schedule set in advance, so those sells say little about the insider's view. The plan box is on filings from April 2023 on.
Members of Congress who traded it
- Alan Armstrong Bought $1,001 - $15,000filed 2026-07-21
Fund holders with contract wins (13F)ⓘ
13F: a quarterly SEC filing in which large investment managers list the US stocks they hold, filed up to 45 days after the quarter.
ⓘ
13F: a quarterly SEC filing in which large investment managers list the US stocks they hold, filed up to 45 days after the quarter.None found.
People and connections
Key people
- MIGNONE ROBERTODirector
- Savage BrianInterim Chief Legal Officer
- Weiss AmirChief Accounting Officer
- Lippman EvanEVP, Business Development
- Zaks Tal ZviDirector
- Hughes Eric ASee "Remarks"
- Jover PlacidSee "Remarks"
- Shields MatthewEVP, Global Operations
- Kalif Eliyahu SharonEVP, Chief Financial Officer
- Lichtenstein ChenDirector
- Nisen PerryDirector
- Elstein AmirDirector
Connections
Connections to other companies, executives and members of Congress, from disclosed trades, shared officers and public filings, are part of Pro. See Pro
Activity
Every record that names this company by ticker, newest first: awards, bills, executive actions, SEC filings, news, private raises and patents.
- NewsBarclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42Aug 12, 2026
- NewsTeva's Re-Rating Still Has Room To RunAug 3, 2026
- NewsAbbVie: Strong Q2 And New Catalysts Keep Me BullishAug 3, 2026
- NewsTeva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call PresentationJul 31, 2026
- NewsuniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter CourseJul 31, 2026
- NewsLow Growth Viatris Is Due For A Pullback After A Stellar 16-Month RunJul 31, 2026
- NewsTeva Stock Rises After Earnings as Revenue Guidance Exceeds ExpectationsJul 29, 2026
- NewsTeva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...Jul 29, 2026
- BillTo amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.Mar 27, 2026
- BillAllowing Greater Access to Safe and Effective Contraception ActMar 25, 2026
- BillTo provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.Mar 12, 2026
- BillSkinny Labels, Big Savings ActDec 5, 2025
- BillElijah E. Cummings Family Asthma ActNov 17, 2025
- BillBiosimilar Red Tape Elimination ActSep 19, 2025
- BillSkinny Labels, Big Savings ActJan 9, 2025
Sources and limits
USAspending (prime contracts only; no subcontracts or classified work; defense contracts can arrive up to 90 days after signing), SEC EDGAR, Senate LDA, FEC, House and Senate disclosures, the Federal Register and the White House. Companies are tied to records by exact name, a verified alias or a subsidiary in the company's own Exhibit 21; a miss is better than a wrong link. A shared date is not proof of cause, and nothing here is investment advice.